Download Files:
Aliskiren (hemifumarate)
$42 – $238
Products Details
Product Description
– Aliskiren (CGP 60536; CGP60536B; SPP 100) hemifumarate is an orally active and selective renin inhibitor, with IC50 of 1.5 nM. Aliskiren hemifumarate can be used for the research of hypertension, cardiovascular diseases and cancer cachexia[1][2][3].
Web ID
– HY-12177
Storage Temperature
– 4°C (Powder, sealed storage, away from moisture)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C64H110N6O16
Citations
– Department of Pharmaceutical Sciences. East Tennessee State University. 2015 May.|Toxicology Research and Application. September 25, 2018.|Toxicology Research and Application. 2018, 2:239784731880115. |Department of Biological Science. National Sun Yat-Sen University. 2015 Sep.|Front Biosci-Landmrk. 2023 Oct 17, 28(10), 238.|Lipids Health Dis. 2018 Jul 31;17(1):183. |Neurobiol Dis. 2014 Nov;71:292-304.
References
– [1]Yuji Nakamura, et al. Discovery of DS-8108b, a Novel Orally Bioavailable Renin Inhibitor. ACS Med. Chem. Lett., 2012, 3 (9), pp 754-758|[2]Buczko W, et al. Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor. Pharmacol Rep. 2008 Sep-Oct;60(5):623-31.|[3]Wood JM, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor.Biochem Biophys Res Commun, 2003, 308(4), 698-705.|[4]Gradman AH, et al.Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation, 2005, 111(8), 1012-1018.|[5]Wang C, et al. Aliskiren targets multiple systems to alleviate cancer cachexia. Oncol Rep. 2016 Nov;36(5):3014-3022. |[6]Ferri N, et al. Aliskiren inhibits prorenin-induced human aortic smooth muscle cell migration. J Renin Angiotensin Aldosterone Syst. 2015 Jun;16(2):284-91.
CAS Number
– 173334-58-2
Molecular Weight
– 1219.59
Compound Purity
– 99.80
SMILES
– O=C(O)/C=C/C(O)=O.O=C(NCC(C)(C(N)=O)C)[C@@H](C[C@@H]([C@H](C[C@@H](C(C)C)CC1=CC=C(OC)C(OCCCOC)=C1)N)O)C(C)C.O=C(NCC(C)(C(N)=O)C)[C@H](C(C)C)C[C@H](O)[C@@H](N)C[C@@H](C(C)C)CC2=CC=C(OC)C(OCCCOC)=C2
Clinical Information
– Launched
Research Area
– Cardiovascular Disease; Cancer
Solubility
– H2O : ≥ 50 mg/mL
Target
– Autophagy;Renin
Pathway
– Autophagy;Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
